LY2157299

Grouped product items
Size	Price	Qty
5mg	$195.00
50mg	$855.00

Catalog Number : 7007224

description

LY2157299 is a potent inhibitor of Transforming Growth factor-Beta Receptor I (TGF-BetaR). TGF-Beta1 is involved in the control of cell growth, proliferation, differentiation, and apoptosis. LY2157299 is reported to disrupt Smad-2 phosphorylation in Human Umbilical Vein Endothelial Cells (HUVEC) and inhibit the growth and migration of tumor cells.

Additional Information

Applications:	FA
Synonyms:	LY 2157299, LY-2157299, Galunisertib
Formulation:	Crystalline solid
Chemical Name:	4-[2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
Molecular Formula:	C₂₂H₁₉N₅O
Molecular Weight:	369.4
CAS Number	700874-72-2
Purity:	≥98%
Storage Conditions:	Product should be kept at -20°C.
References:	Bueno, L., de Alwis, D. P., Pitou, C., Yingling, J., Lahn, M., Glatt, S., & Trocóniz, I. F. (2008). Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. European journal of cancer, 44(1), 142-150. Herbertz, S., Sawyer, J. S., Stauber, A. J., Gueorguieva, I., Driscoll, K. E., Estrem, S. T., ... & Slapak, C. A. (2015). Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway. Drug design, development and therapy, 9, 4479. Maier, A., Peille, A. L., Vuaroqueaux, V., & Lahn, M. (2015). Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts. Cellular Oncology, 38(2), 131-144. Yingling, J. M., Shou, J., Xia, X., Chen, Y., Yan, L., Evans, W., ... & Law, K. (2006). A small molecule inhibitor of TGFβ RI kinase potentiates VEGF dependent angiogenesis in vitro. Cancer Research, 66(8 Supplement), 59-59.